Introduction
T he key to recruiting and retaining safe blood donors is the understanding of infectious markers in the general population to identify low-risk donor populations coupled with an effective donor education, motivation, and recruitment strategy. Voluntary nonremunerated blood donations in India rose from 54.4% in 2006 to 74.1% in January 2010. [1] the late 1990s and early 2000s, and currently around 33 countries in the world have implemented NAT for human immunodeficiency virus (HIV) and around 27 countries for hepatitis B virus (HBV). [2] NAT technique is highly sensitive and specific for viral nucleic acids. It is based on amplification of targeted regions of viral ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) and detects them earlier than the other screening methods thus, narrowing the window period of HIV, HBV, and hepatitis C virus (HCV) infections.
The blood samples can be pooled together in a batch of 6 or 8 before testing to screen a large number of donations with few tests (mini-pool NAT [MPNAT]), or the tests can be run on every individual sample (individual donor NAT [IDNAT] ). It has been debated in various studies whether pooling of samples results in decreased sensitivity of detection as the volume of the individual sample gets lesser in a pool. Therefore, greater the number of samples in a pool, lesser is the sensitivity of detection of the test. Furthermore, the replication rate of HBV is very low, with a mean doubling time of 2.6 days and the viral load is also very low during the window phase. [3, 4] The introduction of NAT for screening pooled or individual donations has led to improved blood safety. The size of MPNAT is considered critical for identification of infected donors, during the preseroconversion phase of infection. A very small size of the pool helps greater reduction in the serological window phase. [5] However, the feasibility of NAT for a developing country like India or its application to Indian blood transfusion service (BTS) has been a topic of debate.
The risk of viral infection is lower today than ever before, due to improvements in donor screening and testing practices. NAT has lowered this risk even further in few centers where this has been adopted. However, this additional benefit comes at an additional cost to the health-care system. [6] Most reports from high prevalence low resource countries showed a yield as high as 1/2800 for HBV and 1/3100 blood donations for HCV with NAT testing. [7] Confidence in results of TTIs in a blood bank is of critical importance. Although enzyme-linked immunosorbent assay blood screening technology relies on the detection of serological markers, these markers may not appear in the blood until up to 3 months after an infection, leaving a "window period" in which a risk of transfusion-transmitted infection is increased. NAT assay reduces this window period by detecting the presence of the viral RNA or DNA directly. Depending on the sensitivity of the test, implementation of HBV NAT has the potential to reduce the risk of infection to levels similar to those for HIV and HCV.
In India, mandatory blood screening for HBV, HIV, and HCV is done by serological tests for hepatitis B surface antigen and antibodies to HIV 1/2 and HCV. The screened seronegative donations are still at risk for TTIs and thus, need for a sensitive screening test arises to decrease this residual risk. This has been reduced significantly over the last two to three decades in western countries where NAT has been implemented. NAT testing has commenced in few centers in India, but it is not a mandatory screening test for TTIs as per Drug and Cosmetics Act, 1940. [8] Major barriers to implementing routine NAT testing in India is its high cost and lack of technical expertise in most of the blood centers. [9] The government of Karnataka becomes the first State Government to implement IDNAT in 2011. Karnataka state has a total of 176 blood banks, with a total collection of around 650,000 units annually. From January 2014, all units under the Department of Health and Family Welfare services are tested at NAT Lab established at Central facility and from September 2014, standalone Regional Blood Transfusion Centre (RBTC) was included in the State Government project.
Aim and objective • To analyze the NAT for our donor population • To demonstrate consolidation of BTS through a centralized testing center for NAT and also to assess safety benefits of implementing IDNAT. Table 1 ]. All the samples were sent for NAT testing. Out of 50,903, total NAT reactive samples were 254, out of this 11 reactive for HIV-1 (0.02%), 2 reactive for HCV (0.003%), 235 (0.46%) reactive for HBV. There was one HIV and 10 HBV infection cases that were not detected by serology but reactive by NAT as shown in Figures 1 and 2 . The yield detected is 0.021% or one in 5000. This yield was found lower than other blood banks participating in the project where it was detected one in 300-500 donations.
Materials and Methods
There are many samples which were reactive with serology but nonreactive with NAT. These could be false positive due to the high sensitivity of chemiluminescence technology. Further investigation has to be done to conclude it.
Discussion
A safe, effective BTS is an essential component in the provision of an adequate health-care service. It is the responsibility of the state to ensure safe blood by improvement of the service through accommodating modern facilities and techniques, establishment of infrastructure, development of workforce, and policies. WHO recommends centralized/regionalized testing as one of the policies to be adopted to improve blood safety.
NAT testing is more sensitive than conventional tests. While the conventional methods depend on antibodies to produce a positive result, NAT is based on the presence of viral genetic material NAT can detect the low levels of viral genetic material present in the body. This happens before the body begins producing antibodies in response to a virus, giving the ability to detect a disease at an earlier stage.
In India, screening for HIV, hepatitis B, and hepatitis C is based on serological testing with the recent introduction of NAT testing in few centers. Even after implementing the more sensitive, newest generation of serological tests, a considerable residual risk of infection remains. [10] Most populations in resource-limited regions suffer from a high prevalence rate of TTIs and are expected to have more frequent incident cases, as well as more occult carriers. Countries with a high prevalence and incidence of infection are likely to yield a significant number of window period donations. Consequently, NAT screening of TTIs in these populations would be expected to identify more yield cases as compared to the developed world and thus to be more cost effective.
In one study from North India, [1] the HBV NAT yield was 1:2972 donations which is much higher than in studies done in Western Europe and the USA, where the reported prevalence is around 1:600,000- Another study from South India shows a NAT yield of 1:53,260 for HIV and 1:26,630 for HBV. The lower NAT yield compared to Jain et al. and Makroo et al. [1, 10] study and Jain et al.'s study is probably on account of the lower seroreactivity rate. The stringent donor screening measures may also have contributed to lower seroreactivity and consequently lower NAT yield in our study. [1, 10, 11] The utility of NAT (NAT yield) will vary based on the donor population, the type of serological test employed, the nature of the kit employed and also based on the sensitivity of NAT test employed. Patterns of infections among blood donors in our country also vary widely, and TTIs continue to be a threat to safe transfusion practices. [12] TTIs is still a major concern to patients, physicians, and policymakers who seek a risk-free blood supply. Results of NAT testing vary significantly based on these factors.
While studies in developing countries have shown high NAT yields, [1, 10] as high as 1/2800 for HBV and 1/3100 blood donations for HCV, other studies in developed countries of Central Europe [13] have shown that yield of NAT using sensitive MPNAT assays is less than expected. After screening 3.6 million donations for HCV and HIV, the NAT yield was found to be 1:600,000 for HCV-RNA and 1 in 1.8 million for HIV-RNA. Another large study in the USA [14] screened 66 million donations by NAT over a 10-year period beginning in 1999 and identified additional 32 HIV cases (NAT yield for HIV 1:2 million) and another 244 HCV cases (NAT yield for HCV 1:270,000).
In India, blood centers are gradually introducing NAT to provide safe blood to their patients. First multicentric study was done by Makroo et al. [10] where a total of 12,224 samples along with their serological results were obtained from eight blood banks in India and were tested individually manually by Procleix Ultrio assay for HIV 1, HCV, and HBV. They observed eight NAT yield cases. This high yield of NAT is due to the high prevalence of TTIs in India, further highlighting the need for NAT in India. In another study from a tertiary care center from North India IDNAT results were compared to serological method for 73,898 samples, 1.49% were reactive by NAT, HIV-1 (0.09%), HCV (0.25%), 1.05% were reactive for HBV only, and around 0.08% were HBV-HCV coinfections with a combined yield of 1 in 610 donations (total 121 NAT yields). [15] NAT is a highly sensitive and advanced technique which has reduced the window period of HBV to 10.34 days, HCV to 1.34 days, and HIV to 2.93 days [16] but it is highly technically demanding, involving issues of high costs, dedicated infrastructure facility, equipment, consumables, and technical expertise. The need for NAT depends on the prevalence and incidence rate of infections in blood donor population, available resources and the evidence of benefit added when combined with serology tests. Hence, the decision of starting NAT should be considered when basic quality assured blood transfusion system is already in place such as volunteer base for blood donation, provision of donor self-deferral, donor notification, and counseling along with quality assured sensitive serological methods for testing TTIs.
Conclusion
• The NAT yield detected in the study was 1 in 5000 which is lower than most of the studies found in India. The implementation of NAT improved blood safety and able to detect window period infection • It has added benefits in blood safety and should be considered along with the basic quality assured blood transfusion system such as volunteer base for blood donation, provision of donor self-deferral, donor notification, and quality assured sensitive serological methods • The NAT consolidation project has helped in reducing window period infections thus reducing the treatment cost and burden on healthcare. The centralization of facility helped in maintaining the quality standards of testing as well in lowering the cost to make it affordable • The centralization of facility helps to bring uniformity in quality control, but such centralized laboratories should go in for mandatory accreditation to assure community confidence. The centralized testing despite economies of scale has not brought down the cost per test significantly. However, the cost of NAT is being subsidized by the state government to make safe blood more affordable.
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